<DOC>
	<DOCNO>NCT00831779</DOCNO>
	<brief_summary>The purpose study evaluate effect dapagliflozin insulin sensitivity</brief_summary>
	<brief_title>Effects Dapagliflozin Insulin Resistance Insulin Secretion Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Subjects type 2 diabetes inadequate glycemic control , define A1C ≥ 7.0 ≤ 10.0 % enrollment visit Subjects receive either metformin therapy OR metformin therapy AND one insulin secretagogue least 12 week prior enrollment Cpeptide ≥ 1.0 ng/ml ( 0.34 nmol/l ) BMI ≤ 45.0 kg/m2 Urine albumin creatinine ratio ( UACR ) &gt; 1,800 mg/g ( 203.4 mg/mmol/Cr ) Aspartate Aminotransferase ( AST ) &gt; 3X Upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) &gt; 3X ULN Serum Total Bilirubin &gt; 2 mg/dL ( 34.2 μmol/l ) Serum Creatinine ( Scr ) ≥ 1.50 mg/dL ( 133 μmol/l ) men ; SCr ≥ 1.40 mg/dL ( 124 μmol/l ) woman Currently unstable serious cardiovascular , renal , hepatic , hematological , oncological , endocrine , psychiatric , rheumatic disease</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>